Smad2 knockdown increases the aggressiveness of metastatic human breast cancer MDA-MB-231 cells while Smad3 knockdown prolongs the latency and delays the growth of bone metastasis, indicating that selective targeting of Smad2 or Smad3 may result in different therapeutic responses34. The gene discussed is SMAD2; the disease is breast carcinoma.